|

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

RECRUITINGEarly 1Sponsored by RayzeBio, Inc.
Actively Recruiting
PhaseEarly 1
SponsorRayzeBio, Inc.
Started2026-06-15
Est. completion2027-08
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Are at least 18 years old at the time of signing the informed consent form (ICF)
* Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC

Exclusion Criteria:

* For Women of Childbearing Potential: Are pregnant or breastfeeding

Note: Additional criteria may apply and will be assessed by the study site

Conditions7

Breast CancerCancerHormone Receptor Positive HER-2 Negative Breast CancerLung CancerMetastatic Urothelial CarcinomaNSCLCTNBC - Triple-Negative Breast Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.